Grab EXTRA 10% OFF all Tangem products. Till Oct 25AstraZeneca invests $2B in Summit; shares surge
6.7 Investments AstraZeneca invests $2B in Summit, boosting shares by up to 20%. The firms will collaborate on cancer trials, especially Ivonescimab. Analysts see strategic benefits for both.
AstraZeneca has announced a $2 billion investment in Summit Therapeutics, resulting in a 15–20% surge in Summit’s stock price during after-hours trading. The investment comes via the purchase of convertible preferred shares at a premium of 10–18.6% over the recent average share price. Both companies plan to expand their collaboration in clinical trials, combining Summit’s Ivonescimab with AstraZeneca’s Sonesitatug-Vedotin, with a focus on gastrointestinal cancers. The agreement is non-exclusive and includes cost-sharing for these studies. Analysts view the deal as strategic validation for Summit and a move that strengthens AstraZeneca’s oncology strategy, without a full acquisition. The investment also addresses Summit’s previous funding concerns. An FDA decision on Ivonescimab for lung cancer is expected on November 14.
